Search


Important Information for the Hemophilia Community Regarding Triad Group’s Alcohol Prep Products and Bayer’s BayCuff™ and First Aid Kit… learn more »

Kogenate FS Logo - antihemophilic factor (recombinant) for the treatment of Hemophilia A

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to AHF. Continue Reading Below »

Real life demands Convenience

Kogenate® FS with BIO-SET®— a self-contained, needleless rFVIII reconstitution system

  • Offers the convenience of fast and easy reconstitution for patients, caregivers, and healthcare professionals

Safe, Easy, Fast

  • User-friendly features help make factor preparation easy
  • No exposed needles during reconstitution
  • Available in a range of product sizes—3000 IU, 2000 IU, 1000 IU, 500 IU, and 250 IU—for flexibility in dose preparation
  • One of the smallest diluent volumes available
    • 2.5 mL for 250 IU, 500 IU, and 1000 IU
    • Vial sizes: 5.0 mL for 2000 IU and 3000 IU vial sizes
Kogenate® FS

Click here to download the Kogenate FS with BIO-SET "How-To" Instructional Sheet.

Kogenate FS with BIO-SET Grab & Go packaging

  • Compact and convenient
  • Convenience and confidence in a small, tamper-evident box
  • Contains materials necessary for safe reconstitution and fast rFVIII treatment
  • BIO-SET reconstitution system integrated with Kogenate® FS
  • Prefilled diluent syringe
  • Terumo® SurFlo® Winged Infusion Set
  • Alcohol swabs, cotton pad, latex-free bandage

Terumo and SurFlo are registered trademarks of Terumo Medical Corporation.

Bayer HealthCare Kogenate FS Antihemophilic Factor Recombinant

INDICATIONS & USAGE

Kogenate® FS, antihemophilic factor (recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Kogenate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

IMPORTANT SAFETY INFORMATION

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to AHF. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Kogenate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For important risk and use information, please see the full prescribing information.

Prescribing Information | Privacy Policy | Terms of Use | Sitemap

© 2010 Bayer HealthCare Pharmaceuticals Inc. All rights reserved.
BAYER, the Bayer Cross, and KOGENATE are registered trademarks of Bayer.
BIO-SET is a trademark of Biodome SAS.

Bayer HealthCare Pharmaceuticals

Kogenate FS Antihemophilic Factor (Recombinant) with BIO-SET Needleless Reconstitution System